SPRY
NASDAQ HealthcareARS Pharmaceuticals, Inc. - Common Stock
Biotechnology
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
๐ Market Data
| Price | $6.24 |
|---|---|
| Volume | 2,501,900 |
| Market Cap | 620.55M |
| Beta | 0.970 |
| RSI (14-Day) | 56.4 |
| 200-Day MA | $8.78 |
| 50-Day MA | $7.57 |
| 52-Week High | $15.09 |
| 52-Week Low | $4.91 |
| Forward P/E | -7.01 |
| Price / Book | 10.11 |
๐ฏ Investment Strategy Scores
SPRY scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (91/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (16/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find SPRY in your text
Paste any article, transcript, or post โ the tool will extract SPRY and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.